Serum sclerostin levels, bone turnover markers and body composition in mild, moderate and severe osteogenesis imperfecta

Bone ◽  
2012 ◽  
Vol 51 (6) ◽  
pp. S10-S11
Author(s):  
R. Kocijan ◽  
C. Muschitz ◽  
K. Amrein ◽  
A. Fahrleitner-Pammer ◽  
P. Pietschmann ◽  
...  
Keyword(s):  
Body Composition ◽  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Turnover Markers ◽  
Turnover Markers

Bone turnover markers in the obese children – relation to gender, body composition and leptin level

2015 ◽  
Vol 21 (4) ◽  
pp. 154-161 ◽  
Author(s):  
Paweł Matusik ◽  
◽  
Magdalena Olszanecka-Glinianowicz ◽  
Jerzy Chudek ◽  
Ewa Małecka-Tendera ◽  
...  
Keyword(s):  
Body Composition ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Obese Children ◽  
Turnover Markers

scholarly journals The Impact of Bisphosphonates on the Osteoclast Cells of Osteogenesis Imperfecta Patients

2018 ◽  
Vol 11 (2) ◽  
pp. 645-651
Author(s):  
Vandana Dhiman ◽  
Anshita Aggarwal ◽  
Sanjay Kumar Bhadada ◽  
Naresh Sachdeva ◽  
Nirmal Raj Gopinathan ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Turnover Markers ◽  
Caspase 3 ◽  
Mononuclear Cells ◽  
Type Iv ◽  
Turnover Markers ◽  
Adynamic Bone ◽  
Study Participants ◽  
The Impact

Bisphosphonates (BPs) are widely used for treatment of osteogenesis imperfecta (OI). However, prolonged use may be associated with suppression of bone turnover, the exact molecular mechanism of which is poorly understood. The objective of this study was to evaluate the effect of zoledronic acid (ZOL) on precursor osteoclasts by studying caspase 3 activity. A total of 15 children participated in the study (n = 10 OI patients, n= 5 controls). Out of the 10 OI children, 5 had received a cumulative dose of <30 mg and 5 received > 30 mg of ZOL. Isolated mononuclear cells were studied for caspase 3 activity from all study participants. The mean age of study participants was 7 ±1.5 years. Six of them had OI type IV, two had type III and one had types I & II each. Radiographs showed “zebra stripe sign” and dense metaphyses; suggestive of acquired osteosclerosis. Bone turnover markers (PINP and CTx) were suppressed in all OI patients compared to controls. Caspase-3 activity was significantly increased in precursor osteoclasts cells at higher doses of BPs (>30 mg). Overzealous use of ZOL in OI suppresses bone turnover markers (P1NP, CTx) causes osteosclerosis and increased expression of caspase 3 activity in precursor osteoclasts which results in adynamic bone.

Bone turnover markers in patients with osteogenesis imperfecta

Bone ◽  
2004 ◽  
Vol 34 (6) ◽  
pp. 1013-1016 ◽  
Author(s):  
Vania Braga ◽  
Davide Gatti ◽  
Maurizio Rossini ◽  
Francesca Colapietro ◽  
Elia Battaglia ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Turnover Markers ◽  
Turnover Markers

scholarly journals AB030. Study of bone turnover markers and treatment monitoring in osteogenesis imperfecta

2017 ◽  
Vol 5 (S2) ◽  
pp. AB030-AB030
Author(s):  
Amr Gouda ◽  
Samia Temtamy ◽  
Ola Ali ◽  
Walaa Nazim ◽  
Mona Aglan ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Turnover Markers ◽  
Treatment Monitoring ◽  
Turnover Markers

scholarly journals Obesity and Bone Loss at Menopause: The Role of Sclerostin

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1914
Author(s):  
Paolo Marzullo ◽  
Chiara Mele ◽  
Stefania Mai ◽  
Antonio Nardone ◽  
Massimo Scacchi ◽  
...  
Keyword(s):  
Body Composition ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Health ◽  
Bone Turnover Markers ◽  
Turnover Markers ◽  
Total Body

Background. Peripheral fat tissue is known to positively influence bone health. However, evidence exists that the risk of non-vertebral fractures can be increased in postmenopausal women with obesity as compared to healthy controls. The role of sclerostin, the SOST gene protein product, and body composition in this condition is unknown. Methods. We studied 28 severely obese premenopausal (age, 44.7 ± 3.9 years; BMI, 46.0 ± 4.2 kg/m2) and 28 BMI-matched post-menopausal women (age, 55.5 ± 3.8 years; BMI, 46.1 ± 4.8 kg/m2) thorough analysis of bone density (BMD) and body composition by dual X-ray absorptiometry (DXA), bone turnover markers, sclerostin serum concentration, glucose metabolism, and a panel of hormones relating to bone health. Results. Postmenopausal women harbored increased levels of the bone turnover markers CTX and NTX, while sclerostin levels were non-significantly higher as compared to premenopausal women. There were no differences in somatotroph, thyroid and adrenal hormone across menopause. Values of lumbar spine BMD were comparable between groups. By contrast, menopause was associated with lower BMD values at the hip (p < 0.001), femoral neck (p < 0.0001), and total skeleton (p < 0.005). In multivariate regression analysis, sclerostin was the strongest predictor of lumbar spine BMD (p < 0.01), while menopausal status significantly predicted BMD at total hip (p < 0.01), femoral neck (p < 0.001) and total body (p < 0.05). Finally, lean body mass emerged as the strongest predictor of total body BMD (p < 0.01). Conclusions. Our findings suggest a protective effect of obesity on lumbar spine and total body BMD at menopause possibly through mechanisms relating to lean body mass. Given the mild difference in sclerostin levels between pre- and postmenopausal women, its potential actions in obesity require further investigation.

scholarly journals Effectsof aerobic and resistance trainings on relation between blood biochemical parameters and body compositionwith bone turnover markers in overweight men

2019 ◽  
Author(s):  
M. Rostamizadeh ◽  
A. Elmieh ◽  
F. Rahmani nia
Keyword(s):  
Body Composition ◽  
Resistance Training ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Biochemical Parameters ◽  
Exercise Group ◽  
Blood Samples ◽  
Blood Biochemical Parameters ◽  
Blood Biochemical ◽  
Turnover Markers

Introdution: The cells rolled in the formation of bone, regulated glucose metabolism, and increased insulin secretion from pancreatic beta cells and modulated the insulin resistance. Therefore, the present study aimed to study the effects of aerobic and resistance exercises on relation between blood biochemical parameters and body composition with bone turnover markers in overweight men. Method: In this quasi-experimental study, a total of 36 overweight, young healthy men (age range28-35 years) were randomly assigned to the control (n=14), aerobic exercise (n=11) and resistance exercise (n=11) groups. In the aerobic exercise group, excercisetraining was performedfor 8weeks, three sessions per week (at 55-85% of HRR), and in the resistance exercise group,exercise training was perfprmed in 8weeks for three sessions per week(at 55-75% of 1RM). Body composition and blood samples were assessed from fasting blood samples before and after the 8-week exercise programme. Data wereanalyzed by t-test and ANOVA by SPSS ver.25 Software. Results: Paired t-test and one-way ANOVA showed that aerobic and resistance training cause the reduction of body composition (P <0.05), increasing the osteocalcin (P = 0.001 and P <0.001) as well as a significant decrease in blood biochemical parameters (P <0.05). Also, Pearson correlation showed that there was no correlation between osteocalcin and blood biochemical parameters and body composition (P <0.05). Conclusion: The results of this study showed that 8 -week exercise trainings increase osteocalcin levels, which is associated with a decrease in body weight and body fat percentage, particularly lipid profiles. However, despite the differences in mean, there was no statistically significant difference between aerobic and resistance training.

Factors associated with bone turnover and speed of sound in early and late-pubertal females

2011 ◽  
Vol 36 (5) ◽  
pp. 707-714 ◽  
Author(s):  
Panagiota Klentrou ◽  
Izabella A. Ludwa ◽  
Bareket Falk
Keyword(s):  
Physical Activity ◽  
Body Composition ◽  
Bone Turnover ◽  
Dietary Intake ◽  
Speed Of Sound ◽  
Bone Turnover Markers ◽  
Serum Levels ◽  
Daily Energy Intake ◽  
Daily Energy ◽  
Turnover Markers

This cross-sectional study examines whether maturity, body composition, physical activity, dietary intake, and hormonal concentrations are related to markers of bone turnover and tibial speed of sound (tSOS) in premenarcheal (n = 20, 10.1 ± 1.1 years) and postmenarcheal girls (n = 28, aged 15.0 ± 1.4 years). Somatic maturity was evaluated using years from age of peak height velocity (aPHV). Daily dietary intake was assessed with a 24-h recall interview, and moderate to very vigorous physical activity (MVPA) was measured using accelerometry. Plasma levels of 25-OH vitamin D, serum levels of insulin-like growth-factor 1 (IGF-1) and leptin, and serum levels of bone turnover markers including osteocalcin (OC), bone-specific alkaline phosphatase (BAP) and cross-linked N-teleopeptide of type I collagen (NTX) were measured using ELISA. OC, BAP, and NTX were significantly higher while IGF-1 and tSOS were lower in the premenarcheal group. The premenarcheal girls were more active and had higher daily energy intake relative to their body mass but there were no group differences in body mass index percentile. Maturity predicted 40%–57% of the variance in bone turnover markers. Additionally, daily energy intake was a significant predictor of OC, especially in the postmenarcheal group. IGF-1 and MVPA were significant predictors of BAP in the group as a whole. However, examined separately, IGF-1 was a predictor of BAP in the premenarcheal group while MVPA was a predictor in the postmenarcheal group. Adiposity and leptin were both negative predictors of tSOS, with leptin being specifically predictive in the postmenarcheal group. In conclusion, while maturity was the strongest predictor of bone markers and tSOS, dietary intake, physical activity, body composition, and hormonal factors further contribute to the variance in bone turnover and bone SOS in young Caucasian females. Further, the predicting factors of bone turnover and tSOS were different within each maturity group.

Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment

2020 ◽  
Vol 33 (11) ◽  
pp. 1391-1397
Author(s):  
Daisuke Harada ◽  
Hiroko Kashiwagi ◽  
Kaoru Ueyama ◽  
Kyoko Oriyama ◽  
Yuki Hanioka ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Strength ◽  
Bone Turnover Markers ◽  
Bone Fragility ◽  
Mineral Density ◽  
Before And After ◽  
Alendronate Treatment ◽  
Z Scores ◽  
Turnover Markers

AbstractObjectivesOsteogenesis imperfecta (OI) is a skeletal dysplasia characterized by recurrent fractures due to congenital bone fragility. The only bisphosphonate approved for OI in Japan is pamidronate (PAM). To investigate whether monthly intravenous alendronate (ALN) infusions can maintain bone strength in OI children following cyclical PAM treatment.MethodsA prospective and non-inferiority study was conducted. Eight school-age OI patients aged 8.5±2.0 years who were treated with cyclical PAM for 6.0±2.3 years were enrolled and switched to monthly intravenous ALN (0.030 mg/kg/month). Changes in L1-4 bone mineral density (BMD) Z-scores, fracture rates, and bone turnover markers for 12 months were analyzed.ResultsAverage BMD Z-scores were −3.0±1.9, −2.9±2.0, and −2.2±2.0 in 12 months before enrollment, at enrollment, and after 12 months of ALN treatment, respectively. BMD Z-scores increased significantly during treatment with both PAM and ALN (p=0.012), and the effect of ALN was not inferior to that of PAM (p=0.67). There was no change in fracture rates (p=0.86) and bone turnover markers during the 12 months before and after enrollment. Additionally, ALN showed no remarkable side effects.ConclusionsOur results suggest that monthly intravenous ALN can maintain bone strength after primary usage of cyclical PAM. We concluded that monthly intravenous ALN as a maintenance treatment following cyclical PAM administration can be an option for OI children.

RELATIONSHIP OF IGF-I, BONE TURNOVER MARKERS, DIET AND BODY COMPOSITION TO BONE MINERAL DENSITY.

2003 ◽  
Vol 35 (Supplement 1) ◽  
pp. S79
Author(s):  
M M. Murphy ◽  
B C. Nindl ◽  
R K. Evans ◽  
C J. Baker-Fulco ◽  
K M. Sheehan ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Body Composition ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Igf I ◽  
Turnover Markers ◽  
Relationship Of

scholarly journals The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta

2012 ◽  
Vol 4 (3) ◽  
pp. 29 ◽  
Author(s):  
Ingmar Ipach ◽  
Torsten Kluba ◽  
Petra Wolf ◽  
Bertram Pontz ◽  
Falk Mittag
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Density ◽  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Turnover Markers ◽  
Total Serum ◽  
Type I ◽  
Urinary Creatinine ◽  
Urine Creatinine ◽  
Turnover Markers

Osteogenesis imperfecta (OI) is characterized by different signs including increased bone fragility, short stature, blue sclera, abnormal tooth growth and often secondary immobility. No curative therapy has been found for this rare disease up to now, and different pharmacological substances have been tried as treatment for severe forms of OI. Promising results were seen with intravenous bisphosphonates in the treatment of patients with OI. The aim of present study was to show the effect of intravenous ibandronate therapy on bone density and bone metabolism markers. We analyzed the data of 27 patients with the diagnosis of OI who were treated off-label with intravenous ibandronate. Ibandronate was administered by intravenous infusion every three months at a dosage of 0.3-2 mg. Bone turnover markers and bone density were measured before starting therapy and every three months during treatment. Bone density was measured by using an ultrasound imaging system providing an accurate image of the calcaneus and by evaluating broadband ultrasound attenuation (BUA). Twenty-seven patients were treated with intravenous iban- dronate during the observation period. 18 were female. The mean age of all patients was 23.9 years ± 19.6 (range 4-63). Seventeen patients were categorized to have OI Type I, 5 patients to have OI Type III and 5 patients to have OI Type IV. There was a statistically significant decrease in total alkaline phosphatase (P&lt;0.0001). We detected also a statistically significant decrease in the ratio urinary deoxypyridinoline/urinary creatinine (P=0.0048) and the ratio urinary pyridinoline/urinary creatinine (P&lt;0.0001) respectively. There was also a statistically significant increase in serum magnesium (P=0.034) and BUA (P=0.0071). No statistically significant changes were seen for total serum calcium (P=0.16), the ratio of urine calcium/urine creatinine (P=0.29), alkaline phosphatase (isoform bone) (P=0.3), procollagen-I-peptide (P=0.5), osteocalcin (P=0.9), serum phosphatase (P=0.71), parathormone (P=0.11) and the ratio urine phosphatase/urine creatinine (P=0.58) Therapy with ibandronate in patients with OI leads to a normalisation of bone turnover markers and increasing bone density. Therefore serum alkaline phosphatase and bone density are possible parameters to monitor bisphosphonate treatment in patients with OI.

Sign in / Sign up

Export Citation Format

Share Document